Table 3 Multivariate Cox proportional analyses for clinical outcomes according to the group of bodyweight.

From: Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease and low bodyweight: results from KNOW-CKD study

Bw (kg)

CVE

Renal event

All-cause mortality

Composite outcome

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Unmatched cohort (n = 2070)

Q1: < 58.5 (n = 515)

 Unadjusted model

2.478 (1.113–5.516)

0.026

1.449 (1.012–2.075)

0.043

1.654 (0.582–4.597)

0.345

1.547 (1.112–2.151)

0.010

 Adjusted model

2.776 (1.077–7.153)

0.035

1.292 (0.873–1.912)

0.200

0.840 (0.235–3.000)

0.789

1.331 (0.928–1.908)

0.120

Q2: 58.5–66.0 (n = 506)

 Unadjusted model

2.381 (1.318–4.302)

0.004

1.187 (0.824–1.710)

0.357

1.174 (0.478–2.880)

0.727

1.566 (1.144–2.144)

0.005

 Adjusted model

1.247 (0.628–2.478)

0.528

0.911 (0.599–1.386)

0.663

0.531 (0.182–1.546)

0.246

1.005 (0.704–1.434)

0.980

Q3: 66.0–74.0 (n = 520)

 Unadjusted model

1.802 (0.910–3.568)

0.091

1.459 (1.025–2.076)

0.036

1.021 (0.444–2.349)

0.961

1.523 (1.110–2.089)

0.009

 Adjusted model

1.325 (0.645–2.722)

0.444

1.068 (0.725–1.573)

0.740

0.419 (0.166–1.060)

0.066

1.037 (0.739–1.455)

0.834

Q4: ≥ 74.0 (n = 529)

 Unadjusted model

2.650 (1.187–5.916)

0.017

1.124 (0.790–1.600)

0.515

1.873 (0.721–4.869)

0.198

1.295 (0.945–1.774)

0.107

 Adjusted model

2.438 (0.926–6.419)

0.071

1.374 (0.924–2.043)

0.116

1.544 (0.474–5.032)

0.471

1.370 (0.959–1.957)

0.083

Matched cohort (n = 1062)

Q1: < 60.0 (n = 240)

 Unadjusted model

3.222 (1.171–8.866)

0.024

1.187 (0.793–1.775)

0.405

0.630 (0.206–1.926)

0.417

1.358 (0.933–1.976)

0.110

 Adjusted model

4.014 (1.253–12.865)

0.019

1.484 (0.946–2.328)

0.086

0.329 (0.077–1.410)

0.134

1.553 (1.024–2.356)

0.038

Q2: 60.0–67.0 (n = 238)

 Unadjusted model

1.191 (0.581–2.439)

0.634

0.813 (0.525–1.258)

0.352

0.315 (0.112–0.884)

0.028

0.910 (0.621–1.332)

0.626

 Adjusted model

1.263 (0.585–2.729)

0.552

0.825 (0.519–1.311)

0.416

0.185 (0.051–0.668)

0.010

0.910 (0.615–1.347)

0.637

Q3: 67.0–75.0 (n = 271)

 Unadjusted model

1.714 (0.623–4.716)

0.297

1.305 (0.832–2.046)

0.246

0.745 (0.308–1.798)

0.512

1.254 (0.843–1.866)

0.264

 Adjusted model

1.464 (0.513–4.175)

0.476

1.145 (0.718–1.828)

0.569

1.233 (0.428–3.558)

0.698

1.095 (0.729–1.643)

0.663

Q4: ≥ 75.0 (n = 268)

 Unadjusted model

1.534 (0.595–3.958)

0.376

0.951 (0.605–1.495)

0.827

2.165 (0.417–11.24)

0.358

0.991 (0.661–1.486)

0.966

 Adjusted model

2.158 (0.676–6.888)

0.194

1.113 (0.682–1.816)

0.670

2.678 (0.335–21.408)

0.353

1.216 (0.782–1.890)

0.386

  1. Adjusted for age, male gender, BMI, smoking, baseline eGFR, previous CVD, diabetes, hypertension, proteinuria, hemoglobin, albumin and total cholesterol levels, and use of medications (RAAS blockers, CCB, beta-blockers, statin, warfarin, and other antiplatelet agents).
Back to article page